Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,855.00    160.00 (2.39%)
Bid:
6,850.00
Ask:
6,865.00
Spread: 15.00 (0.219%)
Market Cap: £5.06b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Interim Management Statement

7 Nov 2012 07:00

RNS Number : 4867Q
Spirax-Sarco Engineering PLC
07 November 2012
 



News Release

 

Wednesday 7th November 2012

INTERIM MANAGEMENT STATEMENT

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement in respect of the period from 1st July 2012 to 6th November 2012.

 

Trading

In the four months ended 31st October, organic sales increased 6%, ahead of the rate of growth reported in the first half year. Notably, Asia Pacific and Watson-Marlow achieved strong double-digit sales growth in the period, followed by a more modest advance in the Americas and slightly reduced sales in our Europe, Middle East and Africa (EMEA) segment. Sales in sterling were ahead 2% in the first ten months of 2012, after including the impact of unfavourable currency movements and two small disposals last year.

 

As anticipated, our trading performance in the four months ended 31st October improved with operating profit 8% ahead at constant currency. Better results were particularly evident in Watson-Marlow, where the planned increases in R&D and market development costs in the first half year are unwinding in the second half. Results also improved in EMEA, as the cost base in Europe is being progressively lowered and the profitability of our Supply operations increased. For the ten months ended 31st October 2012, operating profit was therefore 2% ahead of last year at constant currency, compared with a decline of 3% for the first half year.

 

Financial position

We continue to operate with a strong balance sheet and are steadily reducing and rebalancing our stock position in Europe, although this continues to have a negative impact on the factory loading in our main manufacturing plants in the UK and France. Net cash balances at the end of October 2012 increased to £43m compared with £9m at 30th June 2012, although the interim dividend of £12m will be paid on 9th November. There were no significant events or transactions during the period that resulted in a material impact on the financial position of the Group. The principal risks and uncertainties remain those set out on pages 26 and 27 of the 2011 Annual Report.

 

Outlook

Global macro-economic conditions have weakened in recent months as reflected in slowing rates of GDP growth and industrial output in most geographic regions. Trading conditions in many of our markets have, however, remained more resilient and we have not seen softening in underlying demand. The Group has a favourable weighting to defensive industries such as food & beverage, pharmaceuticals and health care, and maintenance spending by our customers has continued to be positive, even against the deterioration in economic conditions.

 

Our business has other resilient characteristics due to our diverse geographic, industry, customer and product spread, and the large proportion of our sales that derive from maintenance or operating spend by our customers. We are seeing the improvements in our Supply organisation from the site consolidation in the UK and from the previously announced cost reduction programme in Europe, which should be complete by the year-end.

 

Although our forward visibility remains short and we are not immune to a worsening in our markets, which can be reflected fairly quickly in our mid-cycle business, the Board continues to expect the Group to make progress for the full year.

 

 

Enquiries:

Mark E Vernon, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

 

Note

All references above are to adjusted trading results that exclude non-operational items, including the previous announced restructuring costs, amortisation of acquisition-related intangible assets and acquisition and disposal costs.

 

 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,700 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBUGGBGDL
Date   Source Headline
1st Mar 20227:30 amRNSChange of Director Details
31st Jan 20227:00 amRNSCompletion of the acquisition of Cotopaxi
24th Jan 20227:00 amRNSAcquisition to accelerate digital strategy
17th Nov 20217:00 amRNSTrading Update
15th Nov 20211:54 pmRNSDirector/PDMR Shareholding
11th Aug 20214:46 pmRNSCorrection to Dividend Record Date in News Release
11th Aug 20217:00 amRNS2021 Half Year Results
3rd Aug 20217:00 amRNSBoard Changes
22nd Jun 20217:00 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSNew Sustainability Targets Launched
4th Jun 20218:12 amRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSNews Release - Investor Seminar
12th May 20214:53 pmRNSResult of AGM
12th May 20217:00 amRNSAGM TRADING UPDATE
10th May 20219:16 amRNSDirector/PDMR Shareholding
12th Apr 202111:44 amRNSDirector/PDMR Shareholding
26th Mar 20218:12 amRNSDirector/PDMR Shareholding
10th Mar 20217:00 amRNS2020 Preliminary Results
9th Mar 20218:30 amRNSBoard Appointment
7th Jan 20214:05 pmRNSDirector/PDMR Shareholding
14th Dec 202010:00 amRNSDirector/PDMR Shareholding
18th Nov 20207:00 amRNSTrading Update
9th Nov 20209:00 amRNSBoard Appointments
21st Oct 20209:21 amRNSChange of Director Details
12th Oct 20205:08 pmRNSDirector/PDMR Shareholding
12th Oct 202010:00 amRNSDirectorate Change
14th Sep 20208:00 amRNSChief Financial Officer
18th Aug 20204:19 pmRNSDirector/PDMR Shareholding
12th Aug 20207:00 amRNS2020 Half Year Results
6th Aug 20208:00 amRNSAdditional Listing
28th Jul 202012:24 pmRNSSection 430(2b) Companies Act - Nimesh Patel
23rd Jul 20207:30 amRNSChange of Director Details
22nd Jun 20203:39 pmRNSChange of Director Details
22nd Jun 20202:45 pmRNSDirector/PDMR Shareholding
20th May 20209:00 amRNSChange of Director Details
13th May 20204:32 pmRNSResult of AGM
13th May 20207:00 amRNSAGM Statement - Trading Update
28th Apr 202011:30 amRNSDisclosure of Rights attached to Equity Shares
24th Apr 20208:59 amRNSAGM Alternative Arrangements
8th Apr 202010:33 amRNSSection 430(2B) Companies Act 2006 Statement
3rd Apr 202011:14 amRNSDirector/PDMR Shareholding
2nd Apr 20208:00 amRNSSpirax Sarco appoints next Chief Financial Officer
30th Mar 20208:30 amRNSChange of Director Details
13th Mar 20209:48 amRNSDirector/PDMR Shareholding
12th Mar 202012:00 pmRNSDirector/PDMR Shareholding
11th Mar 20207:05 amRNSBoard Change
11th Mar 20207:00 amRNS2019 Preliminary Results
7th Feb 20205:35 pmRNSDirector Declaration
13th Nov 20197:00 amRNSTrading Update
10th Sep 20193:30 pmRNSChange of Director Details

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.